Elevar Aims For Rivoceranib Turnaround After Positive Phase III Update

Despite failing to meet the primary endpoint in recent top-line Phase III results, Elevar Therapeutics (formerly LSK BioPharma) is hopeful that rivoceranib still has potential in late-stage gastric cancer based on generally positive full efficacy data from the global Phase III study presented at ESMO.

Jumping
Rivoceranib To Become First Korea-Developed Cancer Drug Sold Globally? • Source: Shutterstock

US-based bioventure Elevar Therapeutics, formerly known as LSK BioPharma Inc., has unveiled new detailed data from the ANGEL Phase III study with rivoceranib (also known as apatinib), which together with best supportive care in patients with gastric or gastroesophageal junction cancer who had failed at least two prior lines of therapy showed generally positive efficacy.

The data, which followed disappointing top-line results in June (see side box), were presented at the European Society for Medical...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D

Sellas Targets Tambiciclib To Adverse-Risk Frontline AML Patients After Phase II Success

 

The biotech announced positive Phase II data for the drug combined with AbbVie/Roche’s Venclexta and BMS’s Vidaza in relapsed/refractory acute myeloid leukemia.

China’s Mid-Cap Companies Thriving On Big Pharma Deals

 

Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.

In Brief: Nanoscope Ploughs Forward With FDA Application For Retinitis Pigmentosa Gene Therapy

 
• By 

Nanoscope’s experimental gene therapy, MCO-010, is designed to target the broader retinitis pigmentosa population, regardless of the underlying gene mutation, with a completed US regulatory submission expected in early 2026.